Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4104400 | 0.86 | GAA (0.62) | GAAALDH1A1RECQLMEN1KMT2A | |
| SCHEMBL31208305 | 0.86 | GAA (0.62) | GAAALDH1A1RECQLMEN1KMT2A | |
| SCHEMBL3485810 | 0.80 | GAA (0.59) | GAAALDH1A1RECQLMEN1KMT2A | |
| SCHEMBL22326350 | 0.80 | GAA (0.88) | GAAALDH1A1RECQLMEN1KMT2A | |
| SCHEMBL4917285 | 0.80 | GAA (0.54) | GAAALDH1A1RECQLMEN1KMT2A | |
| SCHEMBL1671882 | 0.80 | GAA (0.54) | GAAALDH1A1RECQLMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL3485772 | 0.79 | GAA (0.57) | GAAALDH1A1RECQLMEN1KMT2A | |
| SCHEMBL10601228 | 0.78 | MAOB (0.62) | GAAALDH1A1SMN1; SMN2MAOB | |
| SCHEMBL7969176 | 0.77 | GAA (0.69) | GAAALDH1A1RECQLMEN1KMT2A | |
| SCHEMBL6625137 | 0.77 | GAA (0.69) | GAAALDH1A1RECQLMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180186814-A1 | TRICYCLIC COMPOUND HAVING SULFINYL OR SULFONYL | SHIONOGI & CO., LTD. (JP) | 2018-07-05 | — | — | US | disclosed |
| EP-3318567-A1 | TRICYCLIC COMPOUND HAVING SULFINYL OR SULFONYL | Shionogi & Co., Ltd (JP) | 2018-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186814-A1 | TRICYCLIC COMPOUND HAVING SULFINYL OR SULFONYL | SULT1E1, ABCC5, ABCC4 | GAA 3025/4885ALDH1A1 2855/4885RECQL 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.